<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57094">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362802</url>
  </required_header>
  <id_info>
    <org_study_id>GER-EP-015</org_study_id>
    <nct_id>NCT02362802</nct_id>
  </id_info>
  <brief_title>Myocardial Minimal Damage After Rapid Ventricular Pacing</brief_title>
  <acronym>MyDate</acronym>
  <official_title>Myocardial Minimal Damage After Rapid Ventricular Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the impact of antitachycardia pacing ( ATP) on the myocardial
      tissue with respect to its potential micro damage measured by several myocardial markers,
      especially by high-sensitive TroponinT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High sensitive Troponin</measure>
    <time_frame>14-20 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Antitachycardia Pacing</condition>
  <arm_group>
    <arm_group_label>Antitachycardia Pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Antitachycardia Pacing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Implantable cardioverter defibrillator placement without Antitachycardia Pacing.
Apart from that usual standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardioverter Defibrillator</intervention_name>
    <arm_group_label>Antitachycardia Pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients for de-novo implantation of a transvenous ICD (single chamber, dual
             chamber or cardiac resynchronization tehrapy) with left pectoral device position and
             planned apical location of the right ventricular defibrillation electrode.

        Exclusion Criteria:

          -  Resuscitation, cardiac surgical procedure, acute coronary syndrome, acute myocardial
             infarction, coronary revascularisation, cardioversion or ablation during the past 4
             weeks, if baseline high-sensitive Troponin T is elevated

          -  Known stenosis of coronary vessels with indication for coronary intervention or
             operative revascularisation

          -  Intracardiac thrombus or general contraindication against ventricular burst
             stimulation or intraoperative ICD-testing

          -  Atypical lead implantation with indication for defibrillation threshold testing by
             induction of ventricular fibrillation

          -  Right sided implantation of ICD

          -  Planned electrical cardioversion

          -  Lead explantation or -extraction during procedure

          -  Redo procedure (except of additional implantation of a right ventricular ICD lead)

          -  Present temporary pacemaker electrode

          -  ASA &gt;= IV or NYHA IV

          -  Cardiogenic shock

          -  Pulmonary embolism, cerebrovascular insult or dialysis in the past 4 weeks

          -  Lack of consent of patient

          -  Minority of patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Kolb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum MÃ¼nchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Kolb, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>2020</phone_ext>
    <email>kolb@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Verena Semmler, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>2020</phone_ext>
    <email>semmler@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Kolb, MD</last_name>
      <phone>0049 89 1218-2020</phone>
      <email>kolb@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Christof Kolb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>February 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Deutsches Herzzentrum Muenchen</investigator_affiliation>
    <investigator_full_name>Adnan Kastrati, MD</investigator_full_name>
    <investigator_title>PD Dr. med. C. Kolb</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
